Your browser doesn't support javascript.
loading
Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors.
Berland, Léa; Gabr, Zeina; Chang, Michelle; Ilié, Marius; Hofman, Véronique; Rignol, Guylène; Ghiringhelli, François; Mograbi, Baharia; Rashidian, Mohamad; Hofman, Paul.
Affiliation
  • Berland L; Inserm U1081 Institute for Research on Cancer and Aging, Nice (IRCAN) Team 4, Université Côte d'Azur, Institut Hospitalo Universitaire (IHU) RespirERA, Federation Hospitalo Universitaire (FHU) OncoAge, Nice, France.
  • Gabr Z; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Chang M; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Ilié M; School of Life Science, Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland.
  • Hofman V; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Rignol G; Inserm U1081 Institute for Research on Cancer and Aging, Nice (IRCAN) Team 4, Université Côte d'Azur, Institut Hospitalo Universitaire (IHU) RespirERA, Federation Hospitalo Universitaire (FHU) OncoAge, Nice, France.
  • Ghiringhelli F; Laboratory of Clinical and Experimental Pathology, Institut Hospitalo Universitaire (IHU) RespirERA, Federation Hospitalo Universitaire (FHU) OncoAge, Pasteur Hospital, Université Côte d'Azur, Nice, France.
  • Mograbi B; Institut Hospitalo Universitaire (IHU) RespirERA, Nice, France.
  • Rashidian M; Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, Nice, France.
  • Hofman P; Inserm U1081 Institute for Research on Cancer and Aging, Nice (IRCAN) Team 4, Université Côte d'Azur, Institut Hospitalo Universitaire (IHU) RespirERA, Federation Hospitalo Universitaire (FHU) OncoAge, Nice, France.
Front Immunol ; 15: 1384121, 2024.
Article in En | MEDLINE | ID: mdl-38903504
ABSTRACT
The past decade has witnessed a revolution in cancer treatment, shifting from conventional drugs (chemotherapies) towards targeted molecular therapies and immune-based therapies, in particular immune-checkpoint inhibitors (ICIs). These immunotherapies release the host's immune system against the tumor and have shown unprecedented durable remission for patients with cancers that were thought incurable, such as metastatic melanoma, metastatic renal cell carcinoma (RCC), microsatellite instability (MSI) high colorectal cancer and late stages of non-small cell lung cancer (NSCLC). However, about 80% of the patients fail to respond to these immunotherapies and are therefore left with other less effective and potentially toxic treatments. Identifying and understanding the mechanisms that enable cancerous cells to adapt to and eventually overcome therapy can help circumvent resistance and improve treatment. In this review, we describe the recent discoveries on the onco-immunological processes which govern the tumor microenvironment and their impact on the resistance to PD-1/PD-L1 checkpoint blockade.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Resistance, Neoplasm / Tumor Microenvironment / Immune Checkpoint Inhibitors / Neoplasms Limits: Animals / Humans Language: En Journal: Front Immunol / Front. immunol / Frontiers in immunology Year: 2024 Document type: Article Affiliation country: Francia Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Resistance, Neoplasm / Tumor Microenvironment / Immune Checkpoint Inhibitors / Neoplasms Limits: Animals / Humans Language: En Journal: Front Immunol / Front. immunol / Frontiers in immunology Year: 2024 Document type: Article Affiliation country: Francia Country of publication: Suiza